Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Eli Lilly and Co's investigational compound empagliflozin as an add-on therapy significantly reduced blood glucose and body weight in two newly presented phase III trials


Monday, 16 Jun 2014 11:45am EDT 

Eli Lilly and Co:Two phase III clinical trials studying efficacy and safety of investigational compound empagliflozin in type 2 diabetes (T2D) were presented, Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company announced.In two-year study, empagliflozin demonstrated significantly greater decreases in hemoglobin A1C body weight and blood pressure compared with glimepiride as add-on to metformin in adults with T2D.In 52-week study of obese adults with T2D on high insulin doses with or without metformin, adding empagliflozin to multiple daily insulin injections significantly reduced blood glucose and body weight with lower insulin doses compared with placebo. 

Company Quote

53.562
 --
26 Nov 2014